Prevention of Postoperative Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Standard Treatment

Colorectal Cancer Clinical Trial

Official title:

Exploratory Study on the Prevention of Postoperative Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier Granules With Standard Treatment

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06090994
• Other study ID #: HE-202209
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: October 2023
• Est. completion date: September 2028

Study information

• Verified date: October 2023
• Source: Fudan University
• Contact: Sanjun Cai, PhD
• Phone: +8618121299134
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a prospective, multicenter, and exploratory study aimed at evaluating the effectiveness of Huaier Granules in preventing postoperative recurrence and metastasis of colorectal cancer.

Description:

This study is expected to continuously include 648 colorectal cancer (CRC) patients diagnosed with stage IIC-III and undergoing radical resection (R0) who visited the selected research center from August 2023 to March 2025. Among them, 216 patients in the experimental group who were deemed unsuitable or refused postoperative adjuvant radiotherapy and chemotherapy after radical resection (R0) were included, and all patients received Huaier Granule treatment; The control group included 432 patients who received standard treatment after radical resection (R0). Patients in the experimental group began using Huaier granules within 1-2 months after surgery. The control group patients were treated with a standard radiotherapy and chemotherapy regimen recommended by researchers in combination with the latest guidelines and clinical routines. Patients are followed up every 3 months after enrollment until the end of the study, withdrawal from the study for any reason, or death, whichever occurs first.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 648
• Est. completion date: September 2028
• Est. primary completion date: September 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years old, regardless of gender.

• It is diagnosed as colorectal cancer by histopathology, TNM stage ?C or ?.

• Previously underwent radical resection of colorectal cancer with a postoperative evaluation of R0.

• Prior to surgery, the patient did not receive other anti-tumor treatment and was judged by a doctor to be unsuitable for radiotherapy and chemotherapy (meeting any of the following criteria: ? those who are allergic to chemotherapy drugs and excipients; ? the patient has severe heart, liver, kidney and other dysfunction or serious cardiovascular disease; ? the patient is extremely thin, dehydrated, in poor nutritional status, or in a cachexia state; ? the patient's bone marrow hematopoietic function is inhibited, and white blood cells are less than 2×10^9/L or platelets < 50×10^9/L or severe anemia; ? Concomitant severe infection; ? Other contraindications to radiotherapy and chemotherapy determined by doctors or patients refusing to assist with radiotherapy and chemotherapy,patients in the control group plan to receive standard treatment after surgery.

• ECOG score 0-2 points.

• Agree to receive Huaier Granule treatment after enrollment (only in the experimental group).

• Conscious, capable of language expression or reading, able to communicate normally, and cooperate in completing questionnaire evaluations.

• Volunteer to join this study and sign an informed consent form.

Exclusion Criteria:

• History of merging with other malignant tumors.

• Known to be allergic to the components of Huai Er granules or avoid or use Huaier granules with caution (only in the experimental group).

• Inability to take orally medication (experimental group, control group with oral medication included in standard treatment plan).

• Pregnant or lactating women or planned pregnancy preparation.

• In the past one month, the subjects have received Huaier granules or traditional Chinese patent medicines and simple preparations with similar efficacy or indications to Huaier granules (such as compound cantharides capsules, cinobufacin capsules, Kang'ai injection, Pingxiao tablets,please refer to the instruction manual for details.

• Refusal to cooperate with follow-up.

• Other reasons leading to the researcher's belief that it is not suitable to participate in this study.

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms
• Neoplasm Metastasis
• Recurrence

Intervention

Drug:
• Huaier granule
Oral administration, 10g once, 3 times a day, starting within 1-2 months after surgery. Please refer to the medication manual for specific usage. Continuous use for at least 6 months.

Locations

Country	Name	City	State
China	The First People's Hospital of Changzhou	Changzhou	Jiangsu
China	Zhejiang Cancer Hospita	Hangzhou	Zhejiang
China	Harbin Medical University Cancer Hospital	Harbin	Heilongjiang
China	Jiangsu People's Hospital	Nanjing	Jiangsu
China	Ningbo Medical Center Lihuili Hospital	Ningbo	Zhejiang
China	Renji Hospital,Shanghai Jiao Tong University School of Medicine	Shanghai	Shanghai
China	Ruijin Hospital, Shanghai Jiaotong University School of Medicine	Shanghai	Shanghai
China	Sanjun Cai	Shanghai	Shanghai
China	Northern Jiangsu People's Hospital	Yangzhou	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Changes in carcinoembryonic antigen (CEA) compared to baseline period (difference)	The difference in carcinoembryonic antigen levels between the treatment and baseline periods.	start of treatment until 3-year follow-up
Primary	3-year disease-free survival rate (DFS)	The proportion of surviving patients who did not experience disease recurrence or metastasis within 3 years after R0 surgery.	start of treatment until 3-year follow-up
Secondary	1-year disease-free survival rate (DFS)	The proportion of surviving patients who did not experience disease recurrence or metastasis within 1 years after R0 surgery.	start of treatment until 1-year follow-up
Secondary	2-year disease-free survival rate (DFS)	The proportion of surviving patients who did not experience disease recurrence or metastasis within 2 years after R0 surgery.	start of treatment until 2-year follow-up
Secondary	1-?2 -?3-year overall survival rate	The proportion of patients who survive within 1?2 and 3 years.	start of treatment until 3-year follow-up
Secondary	Quality of Life Score	Evaluation using the EORTC QLQ-C30 (Chinese version) core quality of life scale developed by the European Organization for Cancer Research and Treatment.	baseline period and start of treatment until 3-year follow-up
Secondary	The incidence and severity of adverse events (AE) and severe adverse events (SAE)	The definition and severity grading of AE and SAE refer to the corresponding descriptions in the definition and evaluation section of adverse events, and the incidence rate is defined as the proportion of patients with AE and SAE to the corresponding total population.	start of treatment until 3-year follow-up
Secondary	The incidence and severity of adverse reactions (ADR), severe adverse reactions (SADR), suspicious and unexpected severe adverse reactions (SUSAR)	The definition and severity grading of ADR, severe ADR, and SUSAR refer to the corresponding descriptions in the definition and evaluation section of adverse events. The incidence rate is defined as the proportion of patients with ADR, severe ADR, and SUSAR to the corresponding total population.	start of treatment until 3-year follow-up